Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout

Both doses of once-daily pozdeutinurad (AR882) met the primary efficacy endpoint of sUA reduction at month 6 vs placebo Pozdeutinurad was overall well tolerated, and the safety profile was consistent with previous studies STOCKHOLM, May 21, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today...